Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea

This article was originally published in PharmAsia News

Executive Summary

Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.

You may also be interested in...



Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities

SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said

Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013

SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences

France's Sanofi Scans China And Korea For Partnerships And Acquisitions As Part Of Global R&D Transformation

BEIJING - As part of a radical redesign of its worldwide research and development model, France's Sanofi-Aventis is searching for potential biotechnology partners in China and South Korea, according to Marc Cluzel, who heads Sanofi's global R&D operations

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC084208

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel